By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PsychoGenics Inc. 

765 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-406-8000 Fax: 914-593-0645


PsychoGenics is a contract research organization (CRO) with focus on CNS disorders that offers a wide range of standard and customized preclinical services. PsychoGenics provides a full complement of partnered drug discovery capabilities with a focus on psychiatric, cognitive and neurodegenerative disorders, pain, inflammation, spinal cord and traumatic brain injury.

PsychoGenics' capabilities include behavioral testing across multiple CNS indications with over 80 optimized and validated behavioral tests, specialized preclinical models of CNS diseases (genetic, pharmacological and surgical), and complementary services including:

- A variety of transgenic mouse and rat models including custom breeding in our facility, genotyping, and phenotyping
- Electrophysiology: in vivo single and multi-unit recordings and LTP, slice and in vitro (Dynaflow) recordings. Slice LTP and EEG coming soon
- Molecular and cell biology: qWestern, qPCR, ELISA, microwave technology to assess phosphoproteins and second messengers enrichment in vivo, receptor autoradiography, and in vivo/ex vivo receptor occupancy
- Neurochemistry and microdialysis with multiple analytes assessment in tissue (brain, skin, muscle), CSF, or blood

New service in 2012: Oncology (subcutaneous, intrasplenic and intrahepatic tumor xenograft models)

PsychoGenics’ proprietary technologies are developed to facilitate high throughput, in vivo, compound screening for determination of therapeutic indication, repurposing, lead optimization, safety margin and detailed phenotyping. PsychoGenics transforms drug discovery by combining expertise in behavioral neurobiology with the power of bioinformatics in conjunction with proprietary, high-throughput behavioral testing platforms that rapidly screen compound libraries for CNS activity. These platforms form the core of drug discovery partnerships with major pharmaceutical companies, including Eli Lilly, Roche and Sunovion.

The Highest Quality and Professional Standards
PsychoGenics is committed to excellence in quality at all levels and prides itself on its rigorous quality control procedures. Work is conducted in PsychoGenics' 65,000 sq. ft. AAALAC accredited facilities. No test is offered without extensive validation. Many tests have been validated in multiple strains of mice or rats, and have shown the desired response to standard reference compounds. Studies on client compounds include a standard reference compound where possible.

To learn more, contact us at or visit us at




CEO: Emer Leahy


Please click here for PsychoGenics job opportunities.


All Products

Key Statistics

Ownership: Private

Web Site: PsychoGenics

Company News
PsychoGenics Achieves A Milestone In Drug Discovery Collaboration With Sunovion 6/13/2017 7:50:34 AM
Allergan (AGN) to Consolidate Four New Jersey Locations Into One New U.S. HQ in Madison; PsychoGenics Also Moving In 8/9/2016 5:48:41 PM
PsychoGenics Inc. Drug Discovery Collaboration With Sunovion Pharmaceuticals Inc. Achieves A Milestone 4/4/2016 10:13:30 AM
PsychoGenics Inc. Obtains A License To The Line-41 Mouse Model Of Alzheimer’s Disease 1/27/2016 8:48:50 AM
PsychoGenics Inc. Expands Its Drug Discovery Service Capabilities 1/19/2016 8:15:29 AM
PsychoGenics Inc. And The Alzheimer's Drug Discovery Foundation Announce A Risk-Sharing Partnership For Preclinical Studies 1/12/2016 10:27:39 AM
PsychoGenics Inc. Extends Its Drug Discovery Collaboration With Sunovion Pharmaceuticals Inc. 9/14/2015 12:33:06 PM
PsychoGenics Inc. Obtains A License To Another Transgenic Mouse Model Of α-Synucleinopathies 8/11/2015 10:36:58 AM
PsychoGenics Inc. Obtains A License To ?-Synuclein Transgenic Mouse Models Of Parkinson's Disease 3/18/2015 10:29:53 AM
Resilience And PsychoGenics Inc. Announce A Drug Discovery Partnership 3/2/2015 10:30:04 AM